Literature DB >> 16619268

Serum and glucocorticoid-regulated protein kinases: variations on a theme.

Maude Tessier1, James R Woodgett.   

Abstract

The phosphatidylinositol 3' kinase (PI3K)-signaling pathway plays a critical role in a variety of cellular responses such as modulation of cell survival, glucose homeostasis, cell division, and cell growth. PI3K generates important lipid second messengers-phosphatidylinositides that are phosphorylated at the 3' position of their inositol ring head-group. These membrane restricted lipids act by binding with high affinity to specific protein domains such as the pleckstrin homology (PH) domain. Effectors of PI3K include molecules that harbor such domains such as phosphoinositide-dependent kinase (PDK1) and protein kinase B (PKB), also termed Akt. The mammalian genome encodes three different PKB genes (alpha, beta, and gamma; Akt1, 2, and 3, respectively) and each is an attractive target for therapeutic intervention in diseases such as glioblastoma and breast cancer. A second family of three protein kinases, termed serum and glucocorticoid-regulated protein kinases (SGKs), is structurally related to the PKB family including regulation by PI3K but lack a PH domain. However, in addition to PH domains, a second class of 3' phosphorylated inositol phospholipid-binding domains exists that is termed Phox homology (PX) domain: this domain is found in one of the SGKs (SGK3). Here, we summarize knowledge of the three SGK isoforms and compare and contrast them to PKB with respect to their possible importance in cellular regulation and potential as therapeutic targets. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16619268     DOI: 10.1002/jcb.20894

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  50 in total

1.  MiR-212-3p inhibits glioblastoma cell proliferation by targeting SGK3.

Authors:  Huailei Liu; Chenguang Li; Chen Shen; Fei Yin; Kaikai Wang; Yaohua Liu; Bingjie Zheng; Weiguang Zhang; Xu Hou; Xin Chen; Jianing Wu; Xiaoxiong Wang; Chen Zhong; Jiakang Zhang; Huaizhang Shi; Jing Ai; Shiguang Zhao
Journal:  J Neurooncol       Date:  2015-02-27       Impact factor: 4.130

2.  CISK attenuates degradation of the chemokine receptor CXCR4 via the ubiquitin ligase AIP4.

Authors:  Thomas Slagsvold; Adriano Marchese; Andreas Brech; Harald Stenmark
Journal:  EMBO J       Date:  2006-08-03       Impact factor: 11.598

Review 3.  Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.

Authors:  Seth A Wander; Bryan T Hennessy; Joyce M Slingerland
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

4.  DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.

Authors:  Timothy R Peterson; Mathieu Laplante; Carson C Thoreen; Yasemin Sancak; Seong A Kang; W Michael Kuehl; Nathanael S Gray; David M Sabatini
Journal:  Cell       Date:  2009-05-14       Impact factor: 41.582

5.  Inhibition of serum- and glucocorticoid-inducible kinase 1 enhances TLR-mediated inflammation and promotes endotoxin-driven organ failure.

Authors:  Huaxin Zhou; Shegan Gao; Xiaoxian Duan; Shuang Liang; David A Scott; Richard J Lamont; Huizhi Wang
Journal:  FASEB J       Date:  2015-05-20       Impact factor: 5.191

6.  Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers.

Authors:  Russell Z Szmulewitz; Elizabeth Chung; Hikmat Al-Ahmadie; Silver Daniel; Masha Kocherginsky; Aria Razmaria; Gregory P Zagaja; Charles B Brendler; Walter M Stadler; Suzanne D Conzen
Journal:  Prostate       Date:  2011-05-11       Impact factor: 4.104

Review 7.  Mammalian TOR signaling to the AGC kinases.

Authors:  Bing Su; Estela Jacinto
Journal:  Crit Rev Biochem Mol Biol       Date:  2011-10-10       Impact factor: 8.250

8.  Identification, structure modification, and characterization of potential small-molecule SGK3 inhibitors with novel scaffolds.

Authors:  Grace Qun Gong; Ke Wang; Xin-Chuan Dai; Yan Zhou; Rajesh Basnet; Yi Chen; De-Hua Yang; Woo-Jeong Lee; Christina Maree Buchanan; Jack Urquhart Flanagan; Peter Robin Shepherd; Ying Chen; Ming-Wei Wang
Journal:  Acta Pharmacol Sin       Date:  2018-07-23       Impact factor: 6.150

9.  Identification of Flightless-I as a substrate of the cytokine-independent survival kinase CISK.

Authors:  Jun Xu; Lan Liao; Jun Qin; Jianming Xu; Dan Liu; Zhou Songyang
Journal:  J Biol Chem       Date:  2009-03-17       Impact factor: 5.157

10.  The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid.

Authors:  Han-Kyu Lee; Pravir Kumar; Qinghao Fu; Kenneth M Rosen; Henry W Querfurth
Journal:  Mol Biol Cell       Date:  2009-01-14       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.